Gilead Sciences, Inc.

SNSE:GILDCL Stock Report

Market Cap: CL$142.9t

Gilead Sciences Valuation

Is GILDCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of GILDCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: GILDCL (CLP128950) is trading below our estimate of future cash flow value (CLP248987.92)

Significantly Below Future Cash Flow Value: GILDCL is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GILDCL?

Key metric: As GILDCL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GILDCL. This is calculated by dividing GILDCL's market cap by their current earnings.
What is GILDCL's PE Ratio?
PE Ratio16.9x
EarningsUS$9.22b
Market CapUS$155.82b

Price to Earnings Ratio vs Peers

How does GILDCL's PE Ratio compare to its peers?

The above table shows the PE ratio for GILDCL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.7x
AMGN Amgen
23.8x8.57%US$186.6b
VRTX Vertex Pharmaceuticals
26.1x13.01%US$112.4b
ABBV AbbVie
110.8x25.43%US$394.1b
REGN Regeneron Pharmaceuticals
14.2x11.72%US$62.2b
GILDCL Gilead Sciences
16.9x20.85%CL$155.8b

Price-To-Earnings vs Peers: GILDCL is good value based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (43.7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does GILDCL's PE Ratio compare vs other companies in the Global Biotechs Industry?

31 CompaniesPrice / EarningsEstimated GrowthMarket Cap
GILDCL 16.9xIndustry Avg. 24.9xNo. of Companies31PE020406080100+
31 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GILDCL is good value based on its Price-To-Earnings Ratio (16.9x) compared to the Global Biotechs industry average (24.9x).

Price to Earnings Ratio vs Fair Ratio

What is GILDCL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GILDCL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GILDCL's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GILDCL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCL$128,950.00
CL$144,693.18
+12.21%
9.29%CL$165,020.40CL$111,847.16n/a29
Jun ’27CL$128,950.00
CL$140,805.88
+9.19%
9.29%CL$160,587.00CL$108,842.30n/a29
May ’27CL$128,950.00
CL$142,363.07
+10.40%
9.45%CL$161,820.00CL$110,577.00n/a28
Apr ’27CL$128,950.00
CL$143,737.01
+11.47%
9.91%CL$164,345.40CL$107,737.54n/a28
Mar ’27CL$128,950.00
CL$136,662.27
+5.98%
9.74%CL$154,472.33CL$102,981.55n/a27
Feb ’27CL$79,000.00
CL$121,868.47
+54.26%
10.33%CL$138,942.15CL$90,006.55n/a26
Jan ’27CL$79,000.00
CL$121,093.20
+53.28%
10.48%CL$139,956.75CL$96,048.75n/a26
Dec ’26CL$79,000.00
CL$121,715.32
+54.07%
10.65%CL$142,163.01CL$97,562.85n/a25
Nov ’26CL$79,000.00
CL$122,034.19
+54.47%
10.22%CL$141,337.50CL$98,936.25n/a25
Oct ’26CL$79,000.00
CL$120,616.57
+52.68%
10.19%CL$139,076.75CL$93,996.70n/a25
Sep ’26CL$79,000.00
CL$120,751.48
+52.85%
9.69%CL$138,216.65CL$94,721.90n/a25
Aug ’26CL$79,000.00
CL$114,548.04
+45.00%
11.14%CL$135,716.00CL$88,215.40n/a26
Jul ’26CL$79,000.00
CL$108,785.00
+37.70%
11.26%CL$130,428.20CL$86,641.59n/a26
Jun ’26CL$79,000.00
CL$108,737.08
+37.64%
11.71%CL$132,332.20CL$86,961.16CL$128,950.0026
May ’26CL$79,000.00
CL$108,103.59
+36.84%
12.09%CL$132,556.20CL$87,108.36CL$128,950.0026
Apr ’26CL$79,000.00
CL$104,420.92
+32.18%
13.93%CL$130,866.40CL$76,650.32CL$128,950.0025
Mar ’26CL$79,000.00
CL$103,798.83
+31.39%
11.31%CL$124,775.30CL$78,704.42CL$128,950.0027
Feb ’26CL$79,000.00
CL$99,044.02
+25.37%
12.95%CL$122,988.75CL$71,825.43CL$79,000.0027
Jan ’26CL$79,000.00
CL$98,096.95
+24.17%
12.62%CL$123,956.25CL$72,390.45CL$79,000.0027
Dec ’25CL$79,000.00
CL$94,766.15
+19.96%
12.79%CL$121,766.25CL$67,214.97CL$79,000.0028
Nov ’25CL$79,000.00
CL$83,743.62
+6.00%
13.89%CL$117,135.36CL$65,710.08CL$79,000.0028
Oct ’25CL$72,660.00
CL$78,633.42
+8.22%
14.07%CL$112,008.75CL$64,475.63CL$79,000.0027
Sep ’25CL$72,660.00
CL$76,161.92
+4.82%
14.13%CL$108,632.72CL$62,532.28CL$79,000.0027
Aug ’25CL$72,660.00
CL$78,062.70
+7.44%
15.06%CL$112,643.02CL$63,420.86CL$79,000.0027
Jul ’25n/a
CL$78,122.48
0%
14.22%CL$112,051.59CL$63,087.87CL$79,000.0026
Jun ’25n/a
CL$75,919.79
0%
13.99%CL$107,410.68CL$61,508.68CL$79,000.0026
CL$162.17k
Fair Value
20.5% undervalued intrinsic discount
29
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 08:51
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 65 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays